| Literature DB >> 28659140 |
Peter Žiak1,2, Anders Holm3,4, Juraj Halička3,4, Peter Mojžiš5, David P Piñero6.
Abstract
BACKGROUND: The gold standard treatments in amblyopia are penalizing therapies, such as patching or blurring vision with atropine that are aimed at forcing the use of the amblyopic eye. However, in the last years, new therapies are being developed and validated, such as dichoptic visual training, aimed at stimulating the amblyopic eye and eliminating the interocular supression.Entities:
Keywords: Amblyopia; Dichoptic training; Oculus rift; Stereopsis; Virtual reality
Mesh:
Year: 2017 PMID: 28659140 PMCID: PMC5490155 DOI: 10.1186/s12886-017-0501-8
Source DB: PubMed Journal: BMC Ophthalmol ISSN: 1471-2415 Impact factor: 2.209
Fig. 1Oculus Rift DK2 setup. On the LCD screen what patient sees inside head mounted display is shown
Fig. 2Example of the dichoptic training game seen through the oculus rift head mounted display in virtual reality. The amblyopic eye views the left half of the display in which the patient sees the correct color of the gates in order to flight spaceship throught the blue gates. Spaceship is seen only with the dominant eye, the right part of the figure
Baseline characteristics and results of the sample of patients that performed the virtual reality dichoptic training using the Oculus Rift virtual reality head mounted display
| Patient | Healthy eye (Dsph. Dcyl) | Amblyopic eye (Dsph. Dcyl) | BCVA -before DT | BCVA -after DT | Stereoacuity -before DT | Stereoacuity -after DT | ||
|---|---|---|---|---|---|---|---|---|
| 1 | +0.5 | +1 | −0.5 | +3.50 | 0.9 | 0.9 | nil | nil |
| 2 | +0.75 | +1.5 | +2.37 | +0.75 | 1.3 | 1.3 | nil | 400 |
| 3 | +0.25 | +0.5 | +4.5 | +2.5 | 0.5 | 0.4 | nil | 140 |
| 4 | −2.5 | +1 | −3.5 | +1 | 0.6 | 0.5 | nil | 50 |
| 5 | +0.50 | 0 | +7.00 | +0.5 | 0.4 | 0.3 | 400 | 400 |
| 6 | +2 | +0.5 | +3.00 | +1.0 | 0.4 | 0.3 | 200 | 200 |
| 7 | −0.12 | +0.75 | +1.5 | +1.0 | 0.1 | 0.0 | 70 | 50 |
| 8 | +0.25 | +0.5 | +3.00 | +0.5 | 0.2 | 0.1 | 140 | 20 |
| 9 | +0.75 | 0 | +3.75 | +0.5 | 0.2 | 0.0 | 400 | 160 |
| 10 | +0.25 | +0.5 | +1.00 | +1.5 | 0.3 | 0.0 | 200 | 20 |
| 11 | +0.5 | +0.5 | +4.25 | +1.0 | 0.5 | 0.4 | 400 | 140 |
| 12 | +0.50 | 0 | +2.25 | +1.5 | 0.5 | 0.4 | nil | 400 |
| 13 | +0.25 | 0 | +1.75 | +3.0 | 1.0 | 0.5 | niI | 400 |
| 14 | +0.5 | +1.0 | +2.50 | 0 | 0.3 | 0.3 | 400 | 50 |
| 15 | +0.5 | +0.5 | +4.0 | +1.0 | 0.5 | 0.1 | 160 | 20 |
| 16 | −8.0 | +1.0 | −12.0 | +2 | 1.0 | 0.7 | nil | nil |
| 17 | 0 | 0 | +1.87 | +0.75 | 1.1 | 1.1 | nil | 200 |
Abbreviations: SE sperical equivalent, BCVA best corrected visual acuity, DT dichoptic training
Fig. 3Change in best corrected visual acuity (BCVA) with the treatment for each patient evaluated
Fig. 4Distribution of best corrected visual acuity data in the analyzed sample before and after visual traning
Fig. 5Change in stereoacuity with the treatment for each patient evaluated
Fig. 6Distribution of stereoacuity data in the analyzed sample before and after visual traning